WEKO3
アイテム
A tyrosine-kinase inhibitor enhanced antitumor effects of ROBO1-targeted radioimmunotherapy in an SCLC mouse model
https://repo.qst.go.jp/records/80657
https://repo.qst.go.jp/records/806579b981317-8d41-448c-8ff0-55b8bc675eac
| Item type | 会議発表用資料 / Presentation(1) | |||||
|---|---|---|---|---|---|---|
| 公開日 | 2020-08-25 | |||||
| タイトル | ||||||
| タイトル | A tyrosine-kinase inhibitor enhanced antitumor effects of ROBO1-targeted radioimmunotherapy in an SCLC mouse model | |||||
| 言語 | ||||||
| 言語 | eng | |||||
| 資源タイプ | ||||||
| 資源タイプ識別子 | http://purl.org/coar/resource_type/c_c94f | |||||
| 資源タイプ | conference object | |||||
| アクセス権 | ||||||
| アクセス権 | metadata only access | |||||
| アクセス権URI | http://purl.org/coar/access_right/c_14cb | |||||
| 著者 |
Fujiwara, Kentaro
× Fujiwara, Kentaro× Sudo, Hitomi× Sugyo, Aya× Tsuji, Atsushi× Higashi, Tatsuya× Fujiwara, Kentaro× Sudo, Hitomi× Sugyo, Aya× Tsuji, Atsushi× Higashi, Tatsuya |
|||||
| 抄録 | ||||||
| 内容記述タイプ | Abstract | |||||
| 内容記述 | ROBO1 is a membrane protein that is frequently expressed in small cell lung cancer (SCLC). We previously reported our radioimmunotherapy (RIT) agent 90Y-labeled anti-ROBO1 IgG showed significant anti-tumor effects such as tumor shrinkage, but the tumors showed regrowth, suggesting the necessity for more effective therapy. Here, we evaluated the efficacy of a combination therapy of the RIT agent and a tyrosine-kinase inhibitor nintedanib in SCLC xenograft mice. Four groups of SCLC xenograft mice were treated with saline (control), nintedanib alone, RIT alone, and a combination of RIT and nintedanib, respectively. In the nintedanib alone group, no anti-tumor effects such as tumor growth suppression were observed. The RIT alone group and the combination group showed remarkable tumor shrinkage and prolonged survival compared with the control group. Tumor regrowth was observed in all 6 cases in the RIT alone group and 1 of 6 cases in the combination group by 100 days post-treatment. These results suggest that the tyrosine-kinase inhibitor nintedanib enhances anti-tumor effects of RIT with 90Y-labeled anti-ROBO1 IgG. The combination has the potential as an option for SCLC treatment. | |||||
| 会議概要（会議名, 開催地, 会期, 主催者等） | ||||||
| 内容記述タイプ | Other | |||||
| 内容記述 | 第79回日本癌学会学術総会 | |||||
| 発表年月日 | ||||||
| 日付 | 2020-10-01 | |||||
| 日付タイプ | Issued | |||||
